LIFITEGRAST - Generic Drug Details

What are the generic sources for lifitegrast and what is the scope of patent protection?

Lifitegrast is the generic ingredient in two branded drugs marketed by Eugia Pharma, Ingenus Pharms Llc, Micro Labs, and Bausch And Lomb Inc, and is included in four NDAs. There are ten patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Lifitegrast has one hundred and thirty-five patent family members in twenty-four countries.

Three suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for LIFITEGRAST

International Patents:	135
US Patents:	10
Tradenames:	2
Applicants:	4
NDAs:	4
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	69
Clinical Trials:	22
Patent Applications:	2,051
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LIFITEGRAST
What excipients (inactive ingredients) are in LIFITEGRAST?	LIFITEGRAST excipients list
DailyMed Link:	LIFITEGRAST at DailyMed

Recent Clinical Trials for LIFITEGRAST

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Bausch & Lomb Incorporated	PHASE3
Bausch & Lomb Incorporated	PHASE2
Lunan Better Pharmaceutical Co., LTD.	PHASE3

See all LIFITEGRAST clinical trials

Generic filers with tentative approvals for LIFITEGRAST

Applicant	Application No.	Strength	Dosage Form
		5%	SOLUTION/DROPS;OPHTHALMIC

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for LIFITEGRAST

Drug Class	Lymphocyte Function-Associated Antigen-1 Antagonist
Mechanism of Action	Lymphocyte Function-Associated Antigen-1 Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for LIFITEGRAST

S01XA	Other ophthalmologicals
S01X	OTHER OPHTHALMOLOGICALS
S01	OPHTHALMOLOGICALS
S	Sensory organs

Paragraph IV (Patent) Challenges for LIFITEGRAST

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
XIIDRA	Ophthalmic Solution	lifitegrast	5%	208073	4	2020-07-13

US Patents and Regulatory Information for LIFITEGRAST

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch And Lomb Inc	XIIDRA	lifitegrast	SOLUTION/DROPS;OPHTHALMIC	208073-001	Jul 11, 2016		RX	Yes	Yes				Y
Eugia Pharma	LIFITEGRAST	lifitegrast	SOLUTION/DROPS;OPHTHALMIC	215063-001	Nov 7, 2023		DISCN	No	No
Bausch And Lomb Inc	XIIDRA	lifitegrast	SOLUTION/DROPS;OPHTHALMIC	208073-001	Jul 11, 2016		RX	Yes	Yes			Y	Y
Bausch And Lomb Inc	XIIDRA	lifitegrast	SOLUTION/DROPS;OPHTHALMIC	208073-001	Jul 11, 2016		RX	Yes	Yes			Y
Bausch And Lomb Inc	XIIDRA	lifitegrast	SOLUTION/DROPS;OPHTHALMIC	208073-001	Jul 11, 2016		RX	Yes	Yes			Y
Bausch And Lomb Inc	XIIDRA	lifitegrast	SOLUTION/DROPS;OPHTHALMIC	208073-001	Jul 11, 2016		RX	Yes	Yes
Bausch And Lomb Inc	XIIDRA	lifitegrast	SOLUTION/DROPS;OPHTHALMIC	208073-001	Jul 11, 2016		RX	Yes	Yes			Y

Expired US Patents for LIFITEGRAST

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bausch And Lomb Inc	XIIDRA	lifitegrast	SOLUTION/DROPS;OPHTHALMIC	208073-001	Jul 11, 2016
Bausch And Lomb Inc	XIIDRA	lifitegrast	SOLUTION/DROPS;OPHTHALMIC	208073-001	Jul 11, 2016
Bausch And Lomb Inc	XIIDRA	lifitegrast	SOLUTION/DROPS;OPHTHALMIC	208073-001	Jul 11, 2016
Bausch And Lomb Inc	XIIDRA	lifitegrast	SOLUTION/DROPS;OPHTHALMIC	208073-001	Jul 11, 2016
Bausch And Lomb Inc	XIIDRA	lifitegrast	SOLUTION/DROPS;OPHTHALMIC	208073-001	Jul 11, 2016
Bausch And Lomb Inc	XIIDRA	lifitegrast	SOLUTION/DROPS;OPHTHALMIC	208073-001	Jul 11, 2016

International Patents for LIFITEGRAST

Country	Patent Number	Title	Estimated Expiration
Japan	2014132033	AEROSOLIZED LFA-1 ANTAGONISTS FOR USE IN LOCALIZED TREATMENT OF IMMUNE RELATED DISORDERS
Canada	2985444	COMPOSITIONS ET PROCEDES DE TRAITEMENT DES MALADIES OCULAIRES (COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS)
Mexico	2020001602	INHIBIDOR DEL ANTIGENO-1 ASOCIADO A LA FUNCION DEL LINFOCITO (LFA-1) Y POLIMORFO DEL MISMO. (LFA-1 INHIBITOR AND POLYMORPH THEREOF.)
Israel	239490
European Patent Office	3715345
Spain	2846724
Slovenia	2934510

Supplementary Protection Certificates for LIFITEGRAST

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2444079	C02444079/01	Switzerland		FORMER OWNER: NOVARTIS AG, CH

Market Dynamics and Financial Trajectory for LIFITEGRAST

Last updated: February 17, 2026

Lifitegrast, marketed as Xiidra, is a prescription eye drop developed by Novartis for the treatment of dry eye disease. Its market entry in 2016 has established a significant presence within ophthalmology, driven chiefly by its unique mechanism and regulatory approvals.

---

Market Overview and Adoption Trends

Disease Focus:
Dry eye disease (DED) affects over 16 million Americans and a considerable global population, with an increasing prevalence among aging adults and contact lens users. The chronic nature of DED presents sustained demand.

Product Profile:
Lifitegrast is a small-molecule integrin antagonist targeting lymphocyte function-associated antigen-1 (LFA-1). It reduces inflammation implicated in DED pathophysiology. Its once-daily dosing differentiates it from competitors, such as Cyclosporine (Restasis).

Market Penetration:
As of 2022, Lifitegrast held approximately 20% share within the dry eye therapeutic market, outperforming older treatments but remaining behind artificial tears and other anti-inflammatory agents. Its market share is constrained by:

• Cost considerations (approx. $530 per 60-dose bottle)
• Limited clinician familiarity
• Concerns over long-term efficacy and safety

Competitive Landscape:
Dominated by:

• Cyclosporine (Restasis, Abbott/Astellas)
• Steroid-based therapies (short-term use)
• Emerging Biologics (e.g., Lifitegrast competitors in pipeline)

---

Regulatory and Reimbursement Environment

Regulatory Approvals:
Lifitegrast received FDA approval in July 2016, with subsequent approvals in the EU and other regions. Its approval is based on data demonstrating improvements in signs and symptoms of dry eye.

Reimbursement Dynamics:
Insurance coverage varies, impacting patient access. Immediate post-launch reimbursement policies favored early adoption; however, formulary negotiations have impacted its market penetration.

---

Financial Trajectory

Sales Performance:
Revenue from Lifitegrast (Xiidra) experienced steady growth, reaching approximately $350 million globally in 2022, up from $150 million in 2018. U.S. sales dominate, accounting for roughly 80% of total revenue.

Year	Global Revenue (Millions USD)	U.S. Share (%)	CAGR (2018–2022)
2018	150	80	N/A
2019	220	80	36%
2020	280	80	27%
2021	320	80	14%
2022	350	80	9%

Profitability Outlook:
Gross margins for Lifitegrast are estimated at 60–65%. R&D and marketing expenses offset margins, leading to moderate operating profit margins (~20%). Growth is contingent on increased adoption and off-label use expansion.

Future Revenue Projections:
Analysts project a compound annual growth rate (CAGR) of approximately 8–10% through 2027, reaching $550–$600 million globally, driven by:

• Expanded indications
• Increasing patient awareness
• Pipeline competitors with novel mechanisms

---

Key Market Drivers and Barriers

Drivers:

• Rising prevalence of dry eye due to aging populations
• Increasing off-label use for related ocular inflammatory conditions
• Potential approval of combination therapies

Barriers:

• Competitive pressure from newer agents
• Patent expirations and biosimilar threats
• Cost and reimbursement hurdles

---

Pipeline and Future Outlook

Novartis' pipeline options include:

• New formulations (e.g., sustained-release)
• Combination therapies with other anti-inflammatory agents
• Investigational uses in ocular surface inflammatory diseases

Emerging therapies, such as biologics targeting inflammatory cascades, threaten to disrupt Lifitegrast's market dominance. Regulatory pathways for biosimilars might further compress pricing and margins.

---

Conclusion

Lifitegrast’s market remains robust, with sustained growth driven largely by increasing dry eye prevalence and its clinical profile. However, competitive pressures and evolving reimbursement landscapes present ongoing risks. The trajectory indicates moderate growth, with upside potential if pipeline innovations succeed or if additional indications expand.

---

Key Takeaways

• Lifitegrast generated over $350 million in sales in 2022, with steady annual growth.
• Market share constrained by cost, clinician familiarity, and competition.
• Strong U.S. presence dominates revenue, with growth prospects linked to patient awareness and pipeline development.
• Competitive threats include biologics, biosimilars, and emerging therapies.
• The global market for dry eye treatments is expected to approach $2 billion by 2027.

---

FAQs

1. What are the main factors influencing Lifitegrast’s market growth?
Increasing dry eye prevalence, clinical efficacy, once-daily dosing, and expanding off-label use support growth. Barriers include high treatment costs and competition from biologics and biosimilars.

2. How does Lifitegrast compare with Cyclosporine (Restasis)?
Lifitegrast offers comparable efficacy with a more convenient dosing schedule. It has a faster onset of action, but its overall market share depends on clinician preference and reimbursement policies.

3. What are the key risks for Lifitegrast’s future sales?
Emergence of new therapies, patent expirations, regulatory challenges for new indications, and reimbursement limitations pose significant risks.

4. Are there any pipeline developments that could impact Lifitegrast’s market?
Yes, Novartis is exploring formulations and combination therapies, as well as potential new indications, which could bolster future sales.

5. What is the outlook for Lifitegrast in international markets?
Regulatory approval expansion outside North America is ongoing. Market penetration varies, influenced by local healthcare infrastructure and reimbursement policies.

---

References

[1] Novartis Annual Reports (2018–2022)
[2] IQVIA Sales Data, 2022
[3] FDA Drug Approval Records, 2016
[4] Market Research Future, 2023
[5] GlobalData Reports, 2023